Heart Failure Clinical Trial

Ertugliflozin in Chronic Heart Failure

Summary

The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy.

There are two general purposes for this study. The proposed study is both larger and more rigorous than essentially all PK/PD studies that form the basis of current practice with loop diuretics as well as all studies looking at add-on thiazide therapy (current guideline-recommended adjuvant). The second is to generate a mechanistic understanding of the pleotropic cardio-renal factors with chronic therapy that differentiate ertugliflozin from traditional diuretics particularly in how they maintain reduced blood volume without the complication of over-diuresis and volume depletion.

View Full Description

Full Description

This is a randomized placebo controlled mechanistic study to understand the utility of ertugliflozin in acute and post-acute hospitalized heart failure patients with or without diabetes, compared to both placebo and the active control metolazone. The broad study design will be designed around evaluation of change in gold standard determined body fluid spaces (blood volume, extracellular fluid, total body water), administering a sodium chloride challenge, and collecting the necessary biospecimens to test our hypotheses. The general study design will randomize to ertugliflozin vs. placebo early during IV diuretic therapy with continuation post discharge for a total therapy of 6 weeks.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

A clinical diagnosis of ADHF with at least one objective sign of volume overload (rales, edema, elevated JVP, or preadmission weight gain)
As judged by the treating physician, a projected need and ability to tolerate treatment with an extended need for IV diuretics with the goal of significant fluid removal (i.e., goal >1L/day net fluid loss)
Chronic daily oral loop diuretic dose > or equal to 20mg furosemide equivalents for at least one month prior to admission
eGFR 30 mL/min/1.73 m2
Signed informed consent

Exclusion Criteria:

Current use or plan to initiate renal replacement therapy or ultrafiltration this hospital admission
Significant bladder dysfunction or urinary incontinence
Inability to comply with the serial urine collection procedures
Current use of a thiazide or thiazide like diuretics or use within 5 half-lives of the drug, including metolazone
Prior heart transplant, critical stenotic valvular disease or complex congenital heart
History of type 1 diabetes, diabetic ketoacidosis, "brittle" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 3 months
History of or current urosepsis or frequent urinary tract infections
Anemia with hemoglobin <8g/dL (due to required phlebotomy for the study)
Pregnancy or breastfeeding

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

60

Study ID:

NCT04438213

Recruitment Status:

Recruiting

Sponsor:

Yale University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Yale School of Medicine
New Haven Connecticut, 06510, United States More Info
Jeffrey Testani, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

60

Study ID:

NCT04438213

Recruitment Status:

Recruiting

Sponsor:


Yale University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.